Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Andrew Wiggins *Department of Microbiology, Immunology, and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Umar N Chaudhry *Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Fabiana BisaroDepartment of Microbiology, Immunology, and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Addison LueckDepartment of Microbiology, Immunology, and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Alan A SchmalstigDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Graham F HatfullDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-6705-6821
David B HillMarsico Lung Institute and Lampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9270-777X
Miriam BraunsteinDepartment of Microbiology, Immunology, and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0003-1180-0030
Funding
Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Martina Gentzsch · 2004 to 2026
$26.5M
Bacteriophage diversity, dynamics, function, and exploitationR35GM131729 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Graham F. Hatfull · 2019 to 2026
$3.6M
In vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infectionR01AI176834 · NIAID · COLORADO STATE UNIVERSITY · PI Miriam S. Braunstein, Gauri G Rao · 2024 to 2026
$2.4M
Cystic Fibrosis Foundation BRAUNS21P0Cystic Fibrosis Foundation ESTHER24R0, HILL25G0Cystic Fibrosis Foundation Hatfull19GO, Hatfull21GOEmily's EntourageHoward Hughes Medical Institute GT12053National Institute of Allergy and Infectious Diseases AI007151National Institute of Allergy and Infectious Diseases AI163677National Institute of Allergy and Infectious Diseases AI176834National Science Foundation 2048087NIAID NIH HHS R01 AI176834NIDDK NIH HHS P30 DK065988NIDDK NIH HHS P30DK065988NIGMS NIH HHS GM116884NIGMS NIH HHS R35 GM131729
6 · The paper itself
Abstract
There is a need for new therapies to treat drug-resistant nontuberculous mycobacteria (NTM) disease. Bacteriophages (phages), which are viruses that infect and kill bacteria, are actively being explored as an alternative approach for treating mycobacterial diseases. Several compassionate-use cases of phage therapy for drug-resistant NTM infections exhibit favorable outcomes. To further the development of phage therapy, it is important to recognize and avoid conditions that negatively impact phage activity during phage production, storage, formulation, or treatment. Conversely, there is a need to inactivate free phages in certain preclinical phage therapy experiments. In this study, we investigated three mycobacteriophages BPsΔ
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Inactivating conditions of therapeutic mycobacteriophages. · full record | OpenQuestion